China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk

Dow Jones

02/24

1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com)

(END) Dow Jones Newswires

February 24, 2026 05:05 ET (10:05 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2613794736"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613794736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613794736?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613794736","market":"us","top_or_hot":-1,"title":"China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-24 18:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPHI","symbol_name":"惠普森醫藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613794736","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613794736","pubTimestamp":1771927500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CPHI":"惠普森医药","LABU":"三倍做多标普生物-Direxion"},"translate_title":"中国制药和生物技术公司在强劲盈利后可能会上调指引——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"CPHI":1.5},"content_text":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 05:05 ET (10:05 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}